Article
Optimization of imidazo[4,5-b]pyridine-based kinase inhibitors: identification of a dual FLT3/Aurora kinase inhibitor as an orally bioavailable preclinical development candidate for the treatment of acute myeloid leukemia.
Journal of medicinal chemistry - 25 Oct 2012
Bavetsias Vassilios, Crumpler Simon, Sun Chongbo, Avery Sian, Atrash Butrus, Faisal Amir, Moore Andrew S, Kosmopoulou Magda, Brown Nathan, Sheldrake Peter W, Bush Katherine, Henley Alan, Box Gary, Valenti Melanie, de Haven Brandon Alexis, Raynaud Florence I, Workman Paul, Eccles Suzanne A, Bayliss Richard, Linardopoulos Spiros, Blagg Julian
Abstract excerpt
Optimization of the imidazo[4,5-b]pyridine-based series of Aurora kinase inhibitors led to the identification of 6-chloro-7-(4-(4-chlorobenzyl)piperazin-1-yl)-2-(1,3-dimethyl-1H-pyrazol-4-yl)-3H-imidazo[4,5-b]pyridine (27e), a potent inhibitor of Aurora kinases (Aurora-A K(d) = 7.5 nM, Aurora-B K(d) = 48 nM), FLT3 kinase (K(d) = 6.2 nM), and FLT3 mutants including FLT3-ITD (K(d) = 38 nM) and FLT3(D835Y) (K(d) =...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
